LYEL
Lyell Immunopharma Inc
3월 13일 4:00 PM ET (한국 3/14 05:00)
$21.25
-3.52 ▼ -14.23%
🌙 3월 13일 4:23 PM ET (한국 3/14 05:23)
$21.55
+0.30 ▲ +1.41%
| Index | - | P/E | - | EPS (ttm) | -15.17 | Insider Own | 65.95% | Shs Outstand | 0.02B | Perf Week | -5.39% |
| Market Cap | 0.50B | Forward P/E | - | EPS next Y | 10.37% | Insider Trans | 7.37% | Shs Float | 0.01B | Perf Month | -12.7% |
| Enterprise Value | 0.30B | PEG | - | EPS next Q | -2 | Inst Own | 15.36% | Short Float | 11.28% | Perf Quarter | -32.07% |
| Income | -0.27B | P/S | 12382 | EPS this Y | 45.19% | Inst Trans | 8.1% | Short Ratio | 7.17 | Perf Half Y | 59.77% |
| Sales | 0.00B | P/B | 1.82 | EPS next 5Y | 28.5% | ROA | -66.06% | Short Interest | 0.82M | Perf YTD | -30.96% |
| Book/sh | 11.68 | P/C | 2 | EPS past 3/5Y | -2.7% 0.99% | ROE | -86.98% | 52W High | -52.78% ($45.00) | Perf Year | 75.24% |
| Cash/sh | 10.61 | P/FCF | - | Sales past 3/5Y | -92.48% -65.85% | ROIC | -94.6% | 52W Low | 177.78% ($7.65) | Perf 3Y | -52.35% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 42.18% | Gross Margin | -31952.78% | Volatility(W/M) | 13.62% 10.5% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 7476.25 | Sales Y/Y TTM | -40.98% | Oper. Margin | -566038.89% | ATR (14) | 2.35 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.28 | EPS Q/Q | 54.02% | Profit Margin | -762355.56% | RSI (14) | 39.87 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.28 | Sales Q/Q | -45.45% | SMA20 | -10.13% ($23.65) | Beta | -0.16 | Target Price | $39.33 |
| Payout | - | Debt/Eq | 0.21 | Earnings | 3000000 | SMA50 | -12.68% ($24.34) | Rel Volume | 1.25 | Prev Close | $24.77 |
| Employees | 161 | LT Debt/Eq | 0.17 | EPS/Sales Surpr. | -296.95% -60.78% | SMA200 | 18.94% ($17.87) | Avg Volume(3M) | 0.11M | Price | $21.25 |
| IPO | 2021/6/17 | Option/Short | Yes/Yes | Trades | 2968 | Volume | 141,870 | Change | -14.23% |
뉴스 로딩 중...